Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by PWIB123on Nov 01, 2023 10:02pm
190 Views
Post# 35712621

11% haircut after dilution...I'm expecting further losses

11% haircut after dilution...I'm expecting further lossesThe stock price continues to sink.  Terrible leadership, horrific timing of decisions, and all around bad planning.  I'm not sure how low we will go, but I don't think many investors will do anything to help the cause unless oncology proves out to be a win.  If that doesn't happen, the stock is toast.  What just happened was unforgiveable and will take an overwhelming number of new investors to overcome.  But where are those investors going to come from?  They couldn't get them before due to terrible communication, arrogant disregard, and the worse investor relations I've ever witnessed.  This is dead money unless TH-1902 proves to be a winner.  Honestly, at this point, I'm expecting the worst.
<< Previous
Bullboard Posts
Next >>